Phosphors for Drug Delivery, Medical Imaging and Magnetic Response Comparative Study

Figure 7.2 illustrates the process of active targeting. Nanoparticles can also target cancer through passive targeting. As apoptosis is stopped in cancerous cells, they continue sucking nutritious agents abnormally through the blood vessels forming wide and leaky blood vessels around the cells induced by angiogenesis. Leaky blood vessels are formed due to basement membrane abnormalities and decreased numbers of pericytes lining rapidly proliferating endothelial cells (Hobbs and Seymour 1998). Hence, the permeability of molecules to pass through the vessel wall into the interstitium surrounding tumor cells is increased. The size of the pores in leaky endothelial cells ranges from 100 to 780 nm (Hobes et al. 1998; Rubin and Casarett 1966; Shubik 1982). Thus nanoparticles below that size can easily pass through the pores (Jain and Stylianopoulos 2010; Jang et al. 2003). As a result, it facilitates to efflux the nanoparticles to cluster around the neoplastic cells. Nanoparticles can be targeted to a specific area of capillary endothelium, to concentrate the drug within a particular organ arid perforate the tumor cells by passive diffusion or convection. Lack of lymphatic drainage eases the diffusion process. The tumor interstitium is composed of a collagen network and a gel-like fluid. The fluid has high interstitial pressures which resist the inward flux of molecules. Tumors also lack well-defined lymphatic networks having leaky vasculature. Therefore, drugs that enter the interstitial area may have extended retention times in the tumor interstitium. This feature is called

Active and passive targeting by nanoparticles. (Sutradhar and Amin 2014) Copyright Hindawi Publication House 2014

Fig. 7.2. Active and passive targeting by nanoparticles. (Sutradhar and Amin 2014) Copyright Hindawi Publication House 2014.

S. No.

Author

Synthesis method

Study

Application

Remarks

1.

Grebenik et al. 2014

Biological

tissues is an important focus area of present-day medical diagnostics

Pathogenic tissues, including malignant tumors

New approach to the development of targeted constructs on the basis of UCNP and 4D5 scFv specific to the HER tumor marker

2.

Kantamneni et al. 2017

Real-time surveillance of lesions iir multiple organs should facilitate pre- and post-therapy monitoring in preclinical settings

Major challenge in cancer diagnostics and therapy

3.

Gmeiner and Ghosh 2015

Materials on the nanoscale are increasingly being targeted to cancer cells with great specificity through both active and passive targeting

Use of nanotechnology for cancer treatment with an emphasis on targeted drug delivery

4.

Wang et al. 2013

NIR triggered drug and gene delivery, as well as several other UCNP-based cancer therapeutic

Upconversion nanoparticles for photodynamic therapy and other caiacer therapeutics

NIR-excited PDT or other NIR-triggered theranostics using UCNPs

S.No.

Author

Synthesis method

Study

Application

Remarks

5.

Gupta et al. 2012

Sol-gel technique

Europium-doped yttrium oxide nanophosphors

Nanophosphors in biomedical studies

Fligh-contrast cellular and tissue imaging with high sensitivity, magnetic tracking capability and low toxicity

6.

Feng et al. 2013

Multi-modality bioimaging, and MR light-induced therapy

Developing held, and provide guidance to design and to fabricate new

nanocomposites based on upconversion nanophosphors

7.

Yuan et al. 2012

Great potential to achieving better therapeutic effects in cancer treatment.

Zwitterionic polymer for enhanced drug delivery to tumor

8.

Chen et al. 2013

Mono dispersed biocompatible Yb/Er or Yb/Tm doped p-NaGdF4 upconversion phosphors

Bright luminescence under 1 cm chicken breast tissue

Nanophosphors for deep tissue and dual MRI imaging

9.

Budijono et al. 2010

One-step cothermolysis utilizing oleic acid (OA) and trioctyl phosphine (TOP) ligands

Rare earth ion-doped nanophosphors (NaYF4: Yb3+, Er3+) opens new possibilities for improved biolabelling

Applications in bioimaging and photodynamic therapy

10.

Hou et al. 2011

IBU-loaded a-NaYF4:Yb3+,

Er3+ @silica fibre

nanocomposites

show UC emission of ErJ+

under 980 run NIR laser

excitation

Drug delivery and disease therapy based on its bioactive, luminescent, and porous properties

Upconversion (UC) luminescent porous silica fibres decorated with NaYF4:Yb3+, Er3+ nanocrystals (NCs)

и.

Chen et al. 2013

Drug release as a function of nanoparticle size, shape, surface chemistry, and tissue type

One of the greatest challenges in cancer therapy is to develop methods to deliver chemotherapy agents to tumor cells while reducing systemic toxicity to noncancerous cells

12.

Xu et al. 2011

Solution-phase

synthesis

Drug carrier system varies with the released amount of ibuprofen

Eu3+-doped GdP04 hollow spheres exhibit strong orange-red emission

Biocompatibility test on L929 fibroblast cells using MTT assay reveals low cytotoxicity of the system

13.

Tian et al. 2011

Large scale via a template- directed method using hydro thermal carbon spheres as sacrificed templates

RE ions (Yb/Er) into the Gd203 host matrix, these NPs emitted bright multicolored upconversion

MR/fluorescent imaging and therapeutic applications

Ibuprofen (IBU) was selected as a model drug to study the drug storage and release properties of this system.

S. No.

Author

Synthesis method

Study

Application

Remarks

14.

Chen et al. 2016

For safe and effective therapy, drugs must be delivered efficiently and with minimal systemic side effects

Inorganic drug carriers for cancer therapy

Nanostructures are novel entrants to the world of drug delivery systems. The past decade has witnessed the rapid development of novel nanostructures arid hybrid nanostructures in the field of nanomedicine.

15.

Kang et al. 2011

NaYPiYb^/Er3* nanoparticles via a simple two-step sol- gel process

Nanospheres emit green (2Hu/2 and 4S3/2-4I15/2) and red (4F<,/2f4I15/2) fluorescence of Er3+ even after the loading of IBU

Core shell structured NaYF.iYb^/Er3*® nSi0,@m-Si02 nanospheres are a promising material for controlled drug release

16.

Yi et al. 2014

Hydrothermal conditions using the Gd(0H)C03:Ce/Tb precursor

Three-dimensional (3D) in vivo X-ray bioimaging of the mouse can provide the accurate location from multiple directions

Promising application in targeted therapy of tumors

Ce/Tb co-doped GdP04 hollow' spheres

the Enhanced Permeability and Retention (EPR) effect and facilitates tumor interstitial drug accumulation (Fig. 7.2) (Maeda 2001; Maeda et al. 2000). Ncinoparticles can easily accumulate selectively by enhanced permeability and retention effect and then diffuse into the cells (Yuan 1998).

Very recently, Hyeon and co-workers (Park et al. 2012) reported in vivo PDT effect through the systemic administration of UCNP-Ce6 followed by the 980-nm irradiation (Fig. 7.3). NaGdY4-based UCNPs after PEGylation were loaded with Ce6 molecules by both physical adsorption and chemical conjugation, yielding a UCNP-Ce6 complex with >103 Ce6 molecules per particle. The blood circulation half-life of UCNP-Ce6 was determined to be 21.6 min in BABL/C mice after intravenous injection. Nude mice bearing U87MG tumors were injected with UCNP-Ce6 through the tail vein (0.1 mg of rare earth per mouse). Obvious tumour accumulation of UCNP-Ce6 nanoparticles was revealed by dual-modal upconversion luminescence imaging and Tl-weighted MR imaging (Fig. 7.3 a and b), and could likely be attributed to the Enbumced Permeability and Retention (EPR) effect of cancerous tumors. Under the 980 run irradiation, tumor growth of UCNP- Ce6 injected mice was significantly inhibited compared with other control groups (Fig. 7.3c). These results clearly indicate the great potential of using

In vivo imaging-guided PDT

Fig. 7.3. In vivo imaging-guided PDT. (a) UCL images of nude mice bearing tumors after intravenous injection of UCNP-Ce6. (b) Tl-weighted MR images of a tumourbearing nude mouse before and after 1.5 hours intravenous injection of UCNP-Ce6. (c) Growth of tumors after various treatments indicated for efficient imaging guided PDT therapy. Copyright 2012 Wiley-VCH (Park et al. 2012; Wang et al. 2013).

UCNPs for multi-modal imaging guided PDT. Remarkably, this study is the first report to demonstrate UCNP-based in vivo PDT through the systemic administration of UCNP-PS complexes (Wang et al. 2013).

Recently, Zhang and co-workers (Jayakumar et al. 2012) reported the use of NIR-to-UV UCNPs for photo-controllable gene expression (Fig. 7.4). Plasmid DNA encoding Green Fluorescence Protein (GFP) and small interfering RNA (siRNA) target GFP mRNA were both caged with 4, 5-dimethoxy-2-nitrocicetophenone DMNPE to block their respective functions. After NIR light treatment, they were uncaged by the energy transferred from UCNPs, inducing controlled gene expression £md specific gene silencing, respectively. The NIR-to-UV UCNPs overcome the drawback of current photo-responsive systems in which UV light is needed to activate

Schematic illustration of NIR triggered gene release using NIR-UV UCNPs

Fig. 7.4. Schematic illustration of NIR triggered gene release using NIR-UV UCNPs. (a) Plasmid DNA or siRNA are caged with DMNPE and then uncaged by upconverted UV light emitted from NIR-to-UV UCNPs. Inset shows the penetration depth of UV and NIR light in the skin, (b) Photoactivation and patterned activation of caged GFP nucleic acids in cells. Copyright 2012 Highwire Press PNAS. (Jayakumar et al. 2012).

DMNPE caged nucleic acids. Besides, the upconverted UV produced by the irradiated UCNPs was also found to be relatively safe for the cells, under the applied nanoparticle dosage and duration of NIR laser irradiation. This system was then further used to

Bioluminescence imaging is a technology that allows for the non-invasive study of ongoing biological processes in small laboratory animals. Xing and co-workers (Yang et al. 2012) reported NIR light controlled uncaging of d-luciferin and bioluminescence imaging in vivo using NIR-to-UV UCNP probes. The core-shell NIR-to-UV UCNPs were coated with thiolated silane molecules and subsequently coupled to d-luciferin that was caged with a l-(2-mtrophenyl) ethyl group. UV light emitted from UCNPs under NIR irradiation could activate caged d-luciferin to release d-luciferin molecules which was an active substrate of luciferase used in bioluminescence imaging. Cell viability assays showed no obvious cytotoxicity for C6 glioma cells treated with the d-luciferin/UCNP conjugate after two hours of irradiation with NIR light. In marked contrast, UV irradiation resulted in significant cellular damage after a short exposure time. Importantly, strong bioluminescence signals were detected in the mouse injected d-luciferin/ UCNP conjugate after NIR-light induced photo uncaging. While under UV irradiation, no notable bioluminescence was detected in the mouse owing to the poor tissue penetration of UV light (Fig. 7.5).

 
Source
< Prev   CONTENTS   Source   Next >